NCT01297400View on ClinicalTrials.gov

Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

March 11, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Burns
Interventions
DRUG

Investigational Drug, MW-III

Topical application, twice a day

DRUG

Silvadene® Cream 1% [Silver Sulfadiazine]

Topical application, twice a day

Trial Locations (5)

20010

RECRUITING

MedStar Washington Hospital Center, Washington D.C.

30909

RECRUITING

Joseph M. Still Burn Center, Doctor's Hospital, Augusta

52242

RECRUITING

University of Iowa Health Care, Iowa City

85008

RECRUITING

Valleywise Health Medical Center, Phoenix

95817

RECRUITING

University of CA Davis Medical Center, Sacramento

All Listed Sponsors
lead

Skingenix, Inc.

INDUSTRY